In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning Amvuttra's new ATTR-CM indication approval against competitors in the category.
- The Convergence of Consumer Wellness and Healthcare
- Planning For Perseverance
- Building Uniquity Bio: Teams, Capital, And Strategy
- A Better Way For BD And Commercial Teams To Evaluate Strategic Assets
- Adapting To Change In The Era Of Tariffs, Tax And Regulatory Changes
- Why Empathy Is Your Most Powerful Leadership Tool
- Essential Medicines And The Need For A Robust U.S. Supply Chain
- Navigating Tariffs: Implications And Strategies For Pharmaceuticals Manufacturers
COMPANIES TO WATCH
-
Companies To Watch: Imunon
Imunon aims to shake up the standard of care in the frontline treatment of advanced ovarian cancer.
-
Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of identifying cancer targets on both healthy and diseased cells.
-
Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small molecules.
-
Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, glaucoma, and Fragile X syndrome.
WHERE ARE THEY NOW
-
Where Are They Now? Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and irritation in the eyelid. A new consumer DTC campaign, potential global approvals, and a new indication in the clinic could turn Xdemvy into a blockbuster drug.
-
Where Are They Now? Teva Pharmaceuticals
Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, and branded drugs to set the company back on track, or back to the future.
-
Where Are They Now? Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its founder and mission. But Peter Hecht, Ironwood's former CEO, who now leads Tisento Therapeutics, has practiced what he preached.
NEWSLETTER ARCHIVE
